Sharekhan

Jagsonpal Pharmaceuticals Ltd

Thu 30/04/2026,14:49:46 NSE: JAGSNPHARM

₹ 210.80 1.97 (0.94%)
BUY NOW Buy Jagsonpal Pharmaceuticals Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Jagsonpal Pharmaceuticals Ltd

Thu 30/04/2026,15:3:0

Jagsonpal Pharmaceuticals Ltd

Thu 30/04/2026,14:49:46 | NSE : JAGSNPHARM

₹ 210.801.97 (0.94%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 209.00

Previous Close

₹ 208.83

Volume

227587

Mkt Cap ( Rs. Cr)

₹1415.29

High

₹ 212.90

Low

₹ 205.41

52 Week High

₹ 301.65

52 Week Low

₹ 155.00

Book Value Per Share

₹ 39.31

Dividend Yield

1.91

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Jagsonpal Pharmaceuticals Ltd

Your Vote -

Buy

77.78%

Hold

11.11%

Sell

11.11%

77.78%

9 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

47%

Sell Order Quantity

53%

Bid Price

Qty

210.76

99

211.00

28

211.00

24

211.00

43

211.00

1

Bid Total

68252

Bid Price

Qty

211.00

3169

211.00

95

211.00

47

211.00

1

211.00

40

Bid Total

78260

Option Chain

Analyzes market sentiment, predicts Jagsonpal Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Jagsonpal Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    28 Apr 2026, 6:14PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Link of Recording

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    28 Apr 2026, 6:11PM Audio Recording of Jagsonpal Pharmaceuticals Limited Q4 FY26 Earnings Conference Call on April 28, 2026 at 3:00 P.M

  • Jagsonpal Pharma. - Corporate Action-Board approves Dividend

    27 Apr 2026, 9:27PM Recommendation of Dividend for the financial year ended 31 March, 2026

  • Jagsonpal Pharma. - Record Date

    27 Apr 2026, 8:28PM Jagsonpal Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Buyback is 04-May-2026.

  • Jagsonpal Pharma. - Intimation Of Record Date For The Purpose Of Buy-Back Of Up To 16,00,000 Fully Paid-Up Equity Shares Of \

    27 Apr 2026, 8:27PM Intimation for Record date of Buy Back.

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    27 Apr 2026, 8:21PM Intimation for grant of Employee Stock Options

  • Jagsonpal Pharma. - Updates

    27 Apr 2026, 8:19PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Grant of 1,93,000 ESOP'.

  • Jagsonpal Pharma. - General Updates

    27 Apr 2026, 8:05PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Dividend Update

  • Jagsonpal Pharma. - Press Release

    27 Apr 2026, 7:54PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 27, 2026, titled ""Press Release for Audited Financi

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation

    27 Apr 2026, 7:53PM Press Release for Audited Results for the quarter and year ended March 31, 2026

  • Jagsonpal Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    27 Apr 2026, 7:52PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Presentation

  • Jagsonpal Pharma. - Dividend

    27 Apr 2026, 7:49PM Jagsonpal Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on April 27, 2026, recommended Final Dividend

  • Jagsonpal Pharma. - Outcome of Board Meeting

    27 Apr 2026, 7:47PM Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

  • Jagsonpal Pharma. - Corporate Action-Board to consider Dividend

    27 Apr 2026, 7:43PM Recommendation of Dividend for the Financial Year ended March 31, 2026

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    27 Apr 2026, 7:38PM Press Release for Audited Financial Results for the quarter and year ended March 31, 2026

  • Jagsonpal Pharma. Q4 net profit up 33.13% at Rs 8.76 cr

    27 Apr 2026, 7:20PM The company reported standalone net profit of Rs 8.76 crore for the quarter ended March 31, 2026 as compared to Rs 6.58 crore in the same period last

  • Jagsonpal Pharma. - Audited Financial Results For The Year Ended March 31, 2026

    27 Apr 2026, 7:20PM Audited Financial Results along with Independent Auditor's Review Report for the quarter and year ended March 31, 2026.

  • Jagsonpal Pharma. - Board Meeting Outcome for Outcome Of Board Meeting

    27 Apr 2026, 7:13PM Outcome of Board Meeting held on April 27, 2026 along with Audited (Standalone) Financial \r\nResults for the quarter and year ended March 31, 2026

  • Jagsonpal Pharma. - Press Release

    27 Apr 2026, 7:45AM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 27, 2026, titled ""Press Release on approval of Buy-

  • Jagsonpal Pharma. - Shareholders meeting

    27 Apr 2026, 7:23AM Jagsonpal Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchan

  • Jagsonpal Pharma gets shareholder nod for Rs 40 crore buyback

    27 Apr 2026, 10:39AM Jagsonpal Pharmaceuticals Limited has received shareholder approval for its proposed share buyback, reinforcing its focus on enhancing shareholder val

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    27 Apr 2026, 7:26AM Voting Result of Postal Ballot along with Scrutinizer Report.

  • Jagsonpal Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    22 Apr 2026, 4:24PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    22 Apr 2026, 4:31PM Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure\r\nRequirements) Regulations, 2015, we wis

  • Jagsonpal Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    21 Apr 2026, 5:20PM As of March 2026, 67.89% is owned by Promoters and 32.11% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 25.12% and Fore

  • Jagsonpal Pharma. - Board Meeting Intimation for Prior Intimation Of Board Meeting\r\n

    20 Apr 2026, 5:07PM Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/04/2026 ,inter alia, to con

  • Jagsonpal Pharma. - Copy of Newspaper Publication

    14 Apr 2026, 4:01PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

  • Jagsonpal Pharma. - Updates

    13 Apr 2026, 4:38PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotmen

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    13 Apr 2026, 4:27PM Allotment of 1,76,900 Equity Shares under Jagsonpal Pharmaceuticals Limited Employee Stock Option, Plan 2022

  • Jagsonpal Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Apr 2026, 4:53PM Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026

  • Jagsonpal Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    10 Apr 2026, 4:49PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Jagsonpal Pharma. - Copy of Newspaper Publication

    26 Mar 2026, 4:50PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

  • Jagsonpal Pharma. - Trading Window

    26 Mar 2026, 4:30PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Reg

  • Jagsonpal Pharma. - Shareholders meeting

    25 Mar 2026, 4:59PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about regarding notice of Postal Ballot relating to Approval for buy-back of up to 16,00,0

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    25 Mar 2026, 4:56PM Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015, Please find attached Postal ballot Notice relating to approval for Buy back of upto Rs. 16,

  • Jagsonpal Pharma. - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    13 Mar 2026, 8:25PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

  • Jagsonpal Pharma. - Announcement Under Regulation 30 Of Sebi LODR

    13 Mar 2026, 8:14PM Please find attached disclosure under Regulation 30 of SEBI \r\n(LODR) Regulations, 2015

  • Jagsonpal Pharma. - Press Release

    12 Mar 2026, 2:32PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 12, 2026, titled ""Press Release on announcement of

  • Jagsonpal Pharma. - Buyback

    12 Mar 2026, 2:04PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Buyback

  • Jagsonpal Pharma. - Outcome of Board Meeting

    12 Mar 2026, 2:02PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on March 12, 2026.

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    12 Mar 2026, 2:30PM Please release on announcement of buy back of Equity shares of Company

  • Jagsonpal Pharma. - Board Meeting Outcome for Outcome Of Board Meeting

    12 Mar 2026, 1:57PM Please find attached outcome of meeting held on March 12, 2026 for consideration of buy back of equity shares.

  • Jagsonpal Pharma. - Board Meeting Intimation for Proposal Of Buyback Of Equity Shares Of The Company

    9 Mar 2026, 8:35PM Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/03/2026 ,inter alia, to con

  • Jagsonpal Pharma. - Announcement Under Regulation 30 Of SEBI LODR

    9 Mar 2026, 3:57PM Intimation for grant of employees stock option

  • Jagsonpal Pharma. - Updates

    9 Mar 2026, 3:51PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of 71800 Equity Shares under the Jagsonpal Pharmaceuticals Limited Em

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    9 Mar 2026, 3:49PM Allotment of 71,800 Equity shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022

  • Jagsonpal Pharma. - Updates

    9 Mar 2026, 3:45PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Intimation for grant of Employee Stock Options '.

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    9 Mar 2026, 3:42PM Intimation for grant of Employee stock options
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Jagsonpal Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 276.172 239.95 187.402 158.89 130.8556
Liabilities 276.172 239.95 187.402 158.89 130.8556
Equity 13.393 13.28 13.219 13.099 13.099
Gross Profit 58.074 51.071 23.067 34.151 25.7944
Net Profit 43.082 55.361 22.463 26.721 19.587
Cash From Operating Activities 46.812 55.3 35.166 46.655 5.5981
NPM(%) 14.99 20.6 10.76 11.28 8.66
Revenue 287.225 268.716 208.702 236.714 226.0967
Expenses 229.151 217.645 185.635 202.563 200.3023
ROE(%) 16.32 20.97 8.51 10.12 7.42

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
4 200 1.9 203.67
12 Sep 2025 2.5 125 1.9 240.58
06 Sep 2024 5 100 1.9 351.15
21 Aug 2023 5 100 1.9 352.9
29 Oct 2021 4 80 1.9 162.15
22 Sep 2021 1 20 1.9 157.65
22 Sep 2020 0.5 10 1.9 35.15
20 Sep 2019 0.25 5 1.9 27.1
18 Sep 2018 0.1 2 1.9 26.7
21 Sep 2017 0.1 2 1.9 38.4
21 Sep 2016 0.1 2 1.9 33.85
21 Sep 2015 0.1 2 1.9 26.5
25 Sep 2014 0.5 10 1.9 23.65
25 Sep 2013 0.5 10 1.9 9.5
21 Sep 2012 0.5 10 1.9 12.35
23 Sep 2011 0.5 10 1.9 12.55
21 Sep 2010 0.5 10 1.9 23.85
23 Sep 2009 0.25 5 1.9 12.45
24 Sep 2008 0.1 2 1.9 13.4
21 Sep 2007 0.1 2 1.9 16.7
26 Sep 2006 0.1 2 1.9 19.25
26 Sep 2005 1 20 1.9 55.45
27 Aug 2004 0.5 10 1.9 244.25
30 May 2003 3.75 37.5 1.9 81.15
05 Mar 2002 0 20 1.9 111.85
11 Sep 2001 0 30 1.9 330
0 30 1.9 199

Peers

Other companies within the same industry or sector that are comparable to Jagsonpal Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 712.65 -0.82 42.32 119.19 301.39 0.70
Lotus Eye Hospital and Institute Ltd 118.95 -2.11 383.71 434.33 3.55 0.00
Vaishali Pharma Ltd 7.71 -2.90 0.00 2724.70 3.13 0.00
Astec Lifesciences Ltd 697.90 -0.36 0.00 409.58 -363.15 0.00

Company Info

1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share.2024-The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd.-The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill. 2025-The Company has splits its face value from Rs. 5/- to Rs. 2/-.-The Company has acquire india business of Resilient Cosme-Ceuticals Private Limited along with the brands associated trademarks.

1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share.2024-The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd.-The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill. 2025-The Company has splits its face value from Rs. 5/- to Rs. 2/-.-The Company has acquire india business of Resilient Cosme-Ceuticals Private Limited along with the brands associated trademarks.

Read More

Parent Organisation

Jagsonpal Pharmaceuticals Ltd.

Founded

17/08/1978

Managing Director

Mr.Manish Gupta

NSE Symbol

JAGSNPHARMEQ

FAQ

The current price of Jagsonpal Pharmaceuticals Ltd is ₹ 210.80.

The 52-week high for Jagsonpal Pharmaceuticals Ltd is ₹ 212.90 and the 52-week low is ₹ 205.41.

The market capitalization of Jagsonpal Pharmaceuticals Ltd is currently ₹ 1415.29. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Jagsonpal Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Jagsonpal Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Jagsonpal Pharmaceuticals Ltd shares.

The CEO of Jagsonpal Pharmaceuticals Ltd is Mr.Manish Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT